| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2842
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2008-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2015-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101559596-B1 |
| titleOfInvention |
Engineered anti-alpha v-integrin hybrid antibodies |
| abstract |
The present invention relates to an antibody that specifically binds to an integrin receptor, particularly an alpha V integrin receptor subunit. The antibody comprises a hybrid light chain variable sequence, a mutated heavy chain variable sequence (Fr), and a modified heavy chain constant sequence as well as the antigen binding site (CDR) of a known mouse anti-integrin antibody. The novel antibodies have increased immunogenicity and expression and have resulted in excellent anti-angiogenic activity as well as anti-tumor activity in humans, even in monotherapy, especially when combined with other angiogenesis and tumor suppressor agents. |
| priorityDate |
2007-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |